419 related articles for article (PubMed ID: 25589164)
1. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Di Pasquale G; Zagnoni S; Riva L
Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
3. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
[TBL] [Abstract][Full Text] [Related]
4. How to define valvular atrial fibrillation?
Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
6. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
7. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation - The Fushimi AF Registry.
Doi K; Ogawa H; Ishigami K; Ikeda S; Aono Y; Hamatani Y; Fujino A; An Y; Ishii M; Iguchi M; Masunaga N; Esato M; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M;
Circ J; 2020 Apr; 84(5):714-722. PubMed ID: 32213725
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.
de Souza Lima Bitar Y; Neto MG; Filho JAL; Pereira LV; Travassos KSO; Akrami KM; Roever L; Duraes AR
Drugs R D; 2019 Jun; 19(2):117-126. PubMed ID: 31055767
[TBL] [Abstract][Full Text] [Related]
9. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
Owens RE; Kabra R; Oliphant CS
Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
[TBL] [Abstract][Full Text] [Related]
12. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
Renda G; Ricci F; Giugliano RP; De Caterina R
J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
Al-Najar M; Al-Nusair M; Alrabadi N; Alawaisheh I; Alawaisheh T; Jarrah M; Alzoubi KH; Njem S; Hamoudeh A
Vasc Health Risk Manag; 2023; 19():145-155. PubMed ID: 36968249
[TBL] [Abstract][Full Text] [Related]
14. [Antithrombotic treatment of patients with valvular atrial fibrillation].
Bovin A; Christensen TD; Grove EL
Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
[TBL] [Abstract][Full Text] [Related]
15. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.
Dawwas GK; Barnes GD
Curr Cardiol Rep; 2022 Jun; 24(6):731-738. PubMed ID: 35460473
[TBL] [Abstract][Full Text] [Related]
17. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
18. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
[TBL] [Abstract][Full Text] [Related]
19. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study.
Melgaard L; Jensen M; Overvad TF; Larsen TB; Lip GYH; Nielsen PB
Int J Clin Pract; 2020 Oct; 74(10):e13589. PubMed ID: 32574395
[TBL] [Abstract][Full Text] [Related]
20. Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
Anderson SL; Marrs JC
Curr Cardiol Rep; 2019 Aug; 21(10):118. PubMed ID: 31473836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
